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Abstract
Environmental exposure, genetic modification, and aging are considered risky for Parkinson’s
disease (PD). How these risk factors cooperate to induce progressive neurodegeneration in
PD remains largely unknown. Paraquat is an herbicide commonly used for weed and grass
control. Exposure to paraquat is associated with the increased incidence of PD. In contrast to
familial PD, most sporadic PD cases do not have genetic mutation, but may suffer from partial
dysfunction of neuron-protective genes as aging. Using conditional transgenic RNAi, we
showed that temporal silencing of PINK1 expression in adult mice increased striatal dopamine,
the phenotype that could not be induced by constitutive gene silencing. Moreover, early
exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of PINK1 gene
expression, leading to a significant loss of dopaminergic neurons. Our findings suggest a novel
pathogenesis of PD: exposure to environmental toxicants early in the life reduces the
threshold of developing PD and partial dysfunction of neuron-protective genes later in the life
initiates a process of progressive neurodegeneration to cross the reduced threshold of disease onset.
Key words: Parkinson’s disease; PINK1; pathogenesis; paraquat; RNAi; mice

Introduction
Parkinson disease (PD) results from progressive
degeneration of dopaminergic neurons in the midbrain. PD is characterized by resting tremor, bradykinesia, and muscle rigidity (1). At present, no treatment can protect PD-susceptible neurons or prevent
the disease from progression, although dopamine
replenishment therapy temporally alleviates PD
symptoms (2, 3). Limited knowledge of PD pathogenesis is a major roadblock in the development of
effective therapy for this devastating disease. Recent
advance in epidemiological studies suggests PD as a
multifactorial disease. Aging, genetic and environ-

mental factors are considered risky for PD, but how
these risk factors interact to cause the disease remains
largely unknown.
Occupational exposure to pesticides and cumulative exposure to the herbicide paraquat increase the
risk of developing PD (4, 5). Repeated exposure to
environmental toxicants is associated with the increased risk of PD, but no single environmental toxicant has been definitively linked to PD, suggesting
that the other risk factors must be involved in the
development of sporadic PD. Genetic factors influence the susceptibility to PD. The relatives of PD pa-
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tients show an increased incidence of PD (6). While
most PD cases are sporadic, about 10% of the cases
have pathogenic mutations in the individual genes
including alpha-synuclein, Leucine-Rich Repeat Kinase 2
(LRRK2), parkin, DJ-1, and PTEN-induced putative kinase 1 (PINK1) (7-13). Intriguingly, some PD patients
carry mutation only in the one allele of the recessive
genes parkin and PINK1 and some people carrying
mutation in the dominant gene LRRK2 do not develop
PD in their lives (14-16). The penetrance and expressivity of PD phenotypes appears to be determined not
only by pathogenic mutation in the identified genes,
but also by undefined factors.
Dysfunction of neuron-protective genes and
exposure to toxicants may corporate to induce dopaminergic neurodegeneration in sporadic PD. Indeed,
deletion of the neuron-protective genes such as parkin,
DJ-1, and PINK1 sensitizes dopaminergic neurons to
the toxicants MPTP and paraquat (17-24). Most sporadic PD cases do not have genetic mutation, but they
may suffer from partial dysfunction of neuron-protective genes later in lives. For example, Parkin is S-nitrosylated in PD animal models and in PD
patients (25, 26). S-nitrosylation inhibits Parkin ligase
activity and induces accumulation of improperly
folded and biologically inactive protein, causing a loss
of the neuron-protective functions of Parkin. As aging, some neuron-protective genes may be partially
inactivated due to epigenetic modification. Exposure
to environmental toxicants and genetic failure may
not occur concomitantly, but may occur sequentially.
Perhaps, exposure to environmental toxicants early in
the life causes accumulative effects and sensitizes
dopaminergic neurons to the partial dysfunction of
neuron-protective genes later in the life, causing sporadic PD. To obtain the partial dysfunction of a neuron-protective gene temporally in adult mice, we created conditional PINK1-RNAi transgenic mice, which
were treated with paraquat before the PINK1 gene
was partially silenced in the adulthood. We observed
that early exposure to the environmental toxicant
paraquat sensitized dopaminergic neurons to subsequent dysfunction of the PINK1 gene.

Materials and Methods
Transgenic mice and behavioral analysis
PINK1 RNAi transgenic mice have been characterized (27). Tamoxifen inducible Cre (CreERT)
transgenic mice were purchased from Jackson Laboratories (28). Cre was driven by the ubiquitous hybrid
promoter CAG and was expressed in all tissues (28).
To minimize the leakage of Cre activity, male CreERT
mice were crossed with female PINK1-RNAi mice to
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produce doubly transgenic offspring. Transgenic mice
were identified by PCR analysis of tail DNA as described previously (27). As stated in the results, paraquat (Sigma) was administered to transgenic mice at
the age of 14 days (0.3 mg/kg, subcutaneous injection;
once) or at the age of 12 weeks (10mg/kg, twice a
week, for 3 consecutive weeks). To induce a marked
neurotoxicity, paraquat was repeatedly administered
to selected mice at the postnatal ages and again in the
adulthood. At the age of 16 weeks, selected mice were
injected with 4-hydroxyl Tamoxifen (4-OHT; Sigma)
to induce Cre activity and thus to activate PINK1
RNAi transgene. To achieve a full activation of PINK1
RNAi transgene, 4-OHT was administered by intraperitoneal injection for 5 consecutive days (50
mg/kg/day). The locomotor activity of transgenic
mice within 30 minutes was measured by open field
activity assay (Med Associates). Animal use followed
NIH guidelines and the animal use protocol was approved by the Institutional Animal Care and Use
Committees at the University.

Microdialysis and HPLC analysis
As described previously (29), the extracellular
level of dopamine released into the striatum was
measured by intra-brain microdialysis combined with
HPLC. Anesthetized mice were implanted with a
guide cannula the day before dialysis. On the following day, dialysis probe (BASi) was inserted through
the guide cannula into the left striatum (coordinates:
0.5 mm anterior to bregma; 2 mm left from sagittal
line; 1.5 mm ventral to the skull). Continuous perfusion was maintained with modified Ringer’s solution
(147 mm Na+, 4 mm K+, 1.3 mm Ca2+, 1 mm Mg2+, and
155.6 mm CI-). Dialysates were continuously collected
and the dialysates of every 20-minute were pooled as
one sample for HPLC analysis. Basal dopamine release was established within two hours when comparable levels of dopamine released were obtained in
three consecutive samplings (20 minutes each). The
DAT inhibitor nomifensine was applied to dialysis
solution (200 µM) for 40 minutes (two samplings) and
enhanced dopamine release was then measured. Dopamine concentration in dialysates was instantly
measured by HPLC. The content of striatal dopamine
was measured by HPLC as described previously (27).
Briefly, the striatum was dissected from mouse brain
and was homogenized in 0.1 M perchloric acid. Dopamine in cleared lysates was measured by HPLC.
Tissue pellets were dissolved in 1M NaOH and protein concentration was determined. The contents of
striatal dopamine were adjusted with protein concentration.

http://www.biolsci.org
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Analysis of gene expression by PCR
PCR was done as described previously (30). In
brief, total RNA was isolated from mouse tissues and
the total RNA of 1µg was reversely transcribed to
cDNA with oligo-dT primer (RT kit, Invitrogen). The
resulting cDNA was used PCR amplification. The
following primers were used to amplify specific
mouse genes: primers 5’-GCTTGCCAATCCCT
TCTATG-3’ (forward) and 5’-CTCTCGCTGGAGC
AGTGAC-3’
(reverse)
for
PINK1;
primers
5’-CGGTATAATGGTGGAGTTG-3’ (forward) and
5’-ACCCTTAAGTTCAGCGTTACT-3’ (reverse) for
L17; primers 5’-CAGTGTGGACTTCTACCGTC-3’
(forward) and 5’-AACTGGAGAAGGCAATCAGC-3’
(reverse)
for
DAT;
And
primers
5’CTATCCTCATGGACCACAAC-3’ (forward) and
5’-GCTCAGTCACTCTCAGATTC-3’ (reverse) for
VMAT2. Cycling conditions were 2 min at 94°C followed by 26 or 30 cycles of 15 seconds at 94°C, 30 seconds at 60°C, and 20 seconds at 72°C. PCR products
were resolved on 2% agarose gels.

Histology and stereological cell counting
TH immunostaining and stereological cell
counting were done as described previously (27, 31).
Mouse brain was cut on a Cryostat into serial sections
of 30 µm. Every fourth section through the SNpc was
immunostained for TH (Pel-Freez; 1: 1000). TH positive neurons in the SNpc were estimated by stereological cell counting.

Statistical analysis
Statistical significance among group means was
assessed by ANOVA followed by Tukey’s post hoc
test. In all analyses, the null hypothesis was rejected at
the level of 0.05.

Results
Exposure to the herbicide paraquat increases the
risk of PD (5), and thus we chose paraquat as an example of environmental toxicants. Previous studies
showed that repeated exposure to paraquat causes
severe damage to dopaminergic system (32). To assess
whether early exposure to environmental toxicants
sensitizes dopaminergic neurons to later dysfunction
of neuron-protective genes, we first determined an
optimal dosage of paraquat that is sufficient to induce
a moderate loss of dopaminergic neurons in the
mouse strains established in our lab (Figure 1). We
treated male C57BL6 mice with paraquat by subcutaneous injection and observed a moderate, but significant, loss of dopaminergic neurons in the SNpc
and a marked depletion of striatal dopamine (Figure
1). Some mice were injected of paraquat during post-
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natal development and again in adulthood and a
greater loss of dopaminergic neurons was induced by
repeated exposure to paraquat (Figure 1). Paraquat
caused accumulative damage to dopaminergic neurons in mice. We further examined whether dopaminergic neurotransmission would be compensated
in wildtype mice after the toxicant is removed. As
expected, lost dopaminergic neurons were never restored (Figure 2a). In contrast, synaptic release of
dopamine was significantly increased in the mice after
paraquat was withdrawn (Figure 2b). Synaptic release
of dopamine is virtually related to dopaminergic
function and thus, the findings suggest that the dopaminergic function may be compensated after the
risk factor is removed.
Recessive mutation of the PINK1 gene is linked
to familial PD (10). We chose PINK1 as an example of
neuron-protective genes to examine PD pathogenesis.
We have created conditional transgenic mice that express PINK1 RNAi upon Cre-mediated activation of
the transgene and display a significant knockdown of
PINK1 gene expression by the RNAi (27). Constitutive
depletion of PINK1 by gene knockout or by transgenic
RNAi does not induce dopaminergic neuron death in
the mutant mice (27, 33). To avoid any potential
compensation for gene loss during mouse development, we used inducible Cre to activate PINK1 RNAi
transgene in adult mice and thus to silence PINK1
gene expression in the adulthood (Figure 3a). Similar
to constitutive expression of PINK1 RNAi (27), temporal expression of PINK1 RNAi silenced the expression of PINK1 and did not affect the expression of the
dopamine transporter (DAT) and the vesicular monoamine transporter 2 (VMAT2) genes in transgenic mice
(Figure 3a). Consistent with constitutive gene silencing (27), temporal silencing of PINK1 gene expression
failed to induce dopaminergic neuron death in transgenic mice at advanced ages (Figure 3c). Unexpectedly, temporal silencing of PINK1 gene expression in
adult mice increased striatal dopamine and enhanced
locomotor activity (Figure 3b and 3d). The effect of
PINK1 gene silencing on striatal dopamine was diminished as aging (Figure 3). Temporal silencing of
PINK1 gene expression in adult mice disturbed dopamine homeostasis, uncovering the phenotypes that
were obscured possibly by developmental compensation.
To test whether early exposure to environmental
toxicants sensitizes dopaminergic neurons to partial
dysfunction of neuron-protective genes, we first administered paraquat to PINK1-RNAi transgenic mice
and then silenced the expression of the PINK1 gene by
inducing Cre activity (Figure 3a). Surprisingly, a
greater depletion of striatal dopamine and dopaminhttp://www.biolsci.org
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ergic neurons was induced by a combination of early
exposure to paraquat and subsequent silencing of
PINK1 gene expression, compared to either of the
individual treatments (Figure 4). The results suggest

1183
that environmental exposure and genetic defects may
sequentially occur and synergistically induce a progressive degeneration of dopaminergic neurons in
PD.

Figure 1. Different combination of paraquat and saline was administered to the mice at the postnatal and
the adult ages. a, Stereological cell counting revealed a significant loss of TH-positive neurons in the SNpc of paraquat
(PQ)-treated mice. PQ or saline was administered to male mice at the age of 14 days (0.3mg/kg, once) and further at the age
of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). One week after last PQ injection, the mice were killed for
analysis. b, HPLC analysis revealed the contents of dopamine in the striatum of PQ-treated and –untreated mice. Data are
means ± SEM (n = 7-8). * p < 0.05 compared to the control mice only injected of saline; # p < 0.05 compared to the mice
injected of paraquat at the age of 14 days.

Figure 2. Elevation of dopamine release was observed in mice after PQ treatment. a, Stereological cell
counting revealed no progressive loss of TH-positive neurons in PQ-treated mice after paraquat withdrawal. b, Intra-striatum microdialysis revealed extracellular levels of dopamine released from dopaminergic terminals. Male mice were
injected with PQ at the age of 14 days (0.3mg/kg, once) and further at the age of 12 weeks (10mg/kg, twice a week, for 3
consecutive weeks). Microdialysis was performed in the mice at 1 or 12 weeks after last injection of PQ. By the end of
microdialysis, the mice were terminated for stereological cell counting. Data are means ± SEM (n = 5). * p < 0.05.

http://www.biolsci.org

Int. J. Biol. Sci. 2011, 7

1184

Figure 3. Temporal silencing of PINK1
expression in adult mice disturbed
dopaminergic function. a, PCR analysis
revealed a significant knockdown of PINK1
expression by RNAi. In CreERT and
PINK1-RNAi double transgenic mice, Cre
activity was induced by injection of
4-hydroxyl Tamoxifen (4-OHT). Gene
expression in the midbrain was analyzed by
PCR one month after 4-OHT induction. b,
Locomotor activity in 30 minutes was
measured by open field activity assay. Mice
at the age of 16 weeks were treated with
4-OHT to induce gene silencing and were
tested for locomotor activity at 10 months
and again at 18 months of age. Data are
means ± SEM (n = 6). * p < 0.05. c, Stereological cell counting revealed the number
of TH-positive neurons in the SNpc. Data
are means ± SEM (n = 5). d, HPLC measured the contents of striatal dopamine.
Mice of individual group were terminated at
the age of 10 or 18 months for cell counting. Data are means ± SEM (n = 5). * p <
0.05.

Figure 4. Early exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of PINK1
gene expression. a, HPLC measured the contents of striatal dopamine in mice. The CreERT single (1, untreated control;
3, paraquat) and the CreERT/PINK1-RNAi double transgenic mice (group 2 and 4) were injected with paraquat or saline at
the age of 14 days and further at the age of 12 weeks (10mg/kg, twice a week, for 3 consecutive weeks). One week later, the
mice were injected with 4-OHT to induce Cre activity and thus to activate PINK1-RNAi. At the age of 20 months, the mice
were terminated for analysis. b, Stereological cell counting revealed the number of TH-positive neurons in the SNpc. Data
are means ± SEM (n = 10). * p < 0.05 compared to untreated control; # p < 0.05 compared to group 3 (paraquat).

http://www.biolsci.org

Int. J. Biol. Sci. 2011, 7

Discussion
Exposure to environmental toxicants, genetic
modification of critical genes, and physiological aging
are suggested contributing to PD pathogenesis. We
showed that repeated exposure to paraquat caused
accumulative damage to dopaminergic neurons in
mice. By transgenic RNAi, we silenced PINK1 expression selectively in adult mice and observed a marked
change to dopamine homeostasis that could not be
induced by constitutive silencing of PINK1 expression. Early exposure to paraquat sensitized dopaminergic neurons to subsequent silencing of PINK1
expression in aged mice. Our findings suggest a potential pathogenesis for PD: exposure to environmental toxicants early in the life reduces the threshold
of developing PD; partial dysfunction of neuron-protective genes later in the life continuously
compromises dopaminergic function and eventually
causes the system to cross the reduced threshold of
developing PD.
Paraquat is an herbicide commonly used for
weed and grass control. Exposure to paraquat is associated with the increased risk of PD (5). In the most
studies, paraquat is administered by intraperitoneal
injection and few studies (32) show a statistically significant loss of striatal dopamine content, although a
trend of dopamine loss is always observed. We first
tested intraperitoneal injection of paraquat and observed a severe loss of treated mice (data not shown).
Compared to intraperitoneal injection of MPTP, subcutaneous injection of MPTP induces a more severe
loss of dopaminergic neurons with less variation in
phenotypic expression. We then examined the subcutaneous injection of paraquat and observed a significant loss of striatal dopamine content. Our findings in mice are in great consistency with previous
findings in rats that are subcutaneously injected with
paraquat (34). Intraperitoneal injection may lead to an
abrupt absorption of neurotoxicant such as paraquat
and cause a remarkable fluctuation of blood and tissue paraquat, leading to varied phenotypes. By contrast, subcutaneous injection of paraquat or MPTP
may cause less fluctuation of the chemicals in tissues,
producing a relatively constant effect. Consistent with
previous findings (32, 35-39), our results confirmed
that exposure to paraquat caused substantial and accumulative damage to dopaminergic neurons in mice.
The detrimental effects of environmental toxicants
may accumulate, but may not cause a progressive loss
of dopaminergic neurons unless recurrent exposure to
toxicants happens frequently. In fact, the reduction in
synaptic release of dopamine was partly compensated
after paraquat was removed though the lost neurons
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were never restored. The finding suggests that dopaminergic dysfunction stopped progression after the
environmental toxicant was eliminated. Exposure to
environmental toxicants reduces the threshold of PD
onset, and continuous presence of risk factors is required to induce progressive degeneration of dopaminergic neurons and to cross the reduced threshold
of disease onset. Such a lasting insult is likely from an
endogenous source in sporadic PD.
As aging, the functions of some neuron-protective genes may be compromised (25, 26).
While pathogenic mutation of the two PINK1 alleles
definitely causes PD (10), mutation of the one PINK1
allele also increases PD susceptibility (40, 41), suggesting that PINK1 has dose-dependent effects on
dopaminergic neurons. Unlike familial PD, sporadic
PD may not have inheritable mutation in neuron-protective genes, but may suffer from partial
dysfunction of the beneficial genes later in the life (25,
26). In contrast to previous studies (42-44), our study
applied transgenic RNAi technology to partially silence the expression of the neuron-protective gene
PINK1 selectively in adult mice. Compared to constitutive gene knockout, temporal silencing of PINK1
expression in adult mice increased the content of striatal dopamine, possibly because it avoided developmental compensation for the gene loss. Interestingly,
simultaneous deletion of parkin, DJ-1, and PINK1 also
increases striatal dopamine in the triple knockout
mice at advanced ages (45). By contrast, deleting any
of the three genes (parkin, DJ-1, and PINK1) alone fails
to induce the phenotype in the lifetime of single-gene
knockout mice (33, 46-48). Intriguingly, striatal dopamine was decreased to the control level in our
PINK1-RNAi mice at advanced ages. Alteration to
dopamine neurotransmission may be an early event
in the process of dopaminergic neurodegeneration.
Given that environmental toxicants cause accumulative damage to dopaminergic neurons, exposure
to toxicants any time in the life will reduce the
threshold of developing PD and will increase the incidence of PD. Immature brain is vulnerable to neurotoxins (32), and exposure to environmental toxicants early in the life may play an important role in
PD pathogenesis. Previous studies have shown that
complete and constitutive deletion of neuron-protective genes such as parkin, DJ-1, and PINK1
sensitizes dopaminergic neurons to neurotoxins
(17-24). Previous studies all test the effects of environmental toxicants on dopaminergic system after a
neuroprotective gene is permanently inactivated in
mice. By striking contrast, we used a reverse order of
gene-environment interaction to examine how PD
risky factors corporate to induce the disease. We ashttp://www.biolsci.org
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sessed the effects of early paraquat treatment on the
phenotypic expression caused by partial and temporal
depletion of the PINK1 gene, testing a new theory on
PD pathogenesis. Conditional transgenic RNAi provides an unprecedented tool for temporal, partial
gene depletion in animal models. Temporal silencing
of PINK1 expression by transgenic RNAi induced a
significant loss of dopaminergic neurons in aged
mice, which received paraquat treatment early in their
lives. Endogenous and exogenous toxins may execute
toxicity to dopaminergic neurons via varying mechanisms (49-53). Since RNAi may cause nonspecific toxicity or side-effects, it could not be ruled out whether
the outcome in PINK1-RNAi transgenic mice is a
combined effect of environmental toxicant, gene silencing, and RNAi toxicity. Regardless of mechanisms, sequential insults from multiple hits may cause
accumulative damage to dopaminergic neurons and
any lasting insults may initiate a progressive degeneration of dopaminergic neurons, inducing PD onset.
The novelty of this hypothetic PD pathogenesis warrants further clinical and epidemiological studies.
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